Dissecting the impact of E-cadherin loss on the immune microenvironment. Presented by Kathryn Hacker Gessner Urology@UNC. #BCANTT24 written coverage by Rashid K. Sayyid > bit.ly/4dGMVFd Bladder Cancer Advocacy Network

#BladderCancer surveillance: Is less more? Presented by Mary Beth Westerman LSU Department of Urology. #BCANTT24 written coverage by Rashid K. Sayyid > bit.ly/4cjvidj Bladder Cancer Advocacy Network

Join Rashid K. Sayyid & Zach Klaassen as they delve into the National Comprehensive Cancer Network (NCCN) guidelines for #ProstateCancer, spotlighting relugolix for #mCSPC, insights from #HERO and the rapid and effective testosterone suppression, CV benefits, and integration into adv treatment > bit.ly/45vhkTY

#WatchNow Rashid K. Sayyid University of Toronto and Zach Klaassen Georgia Cancer Center discuss the Society for Immunotherapy of Cancer and the IBCG recommendations for clinical trials in #BladderCancer in this conversation on UroToday > bit.ly/4c3WwFE

Novel treatment targets in the #mCRPC disease space. Rashid K. Sayyid University of Toronto and Zach Klaassen Georgia Cancer Center discuss emerging therapeutic targets and/or applications of existing agents on UroToday> bit.ly/3ucYtOO

#NewVideo #Alert 2024 National Comprehensive Cancer Network (NCCN) Guidelines update: metastatic castration-resistant #ProstateCancer treatment. Rashid K. Sayyid & Zach Klaassen discuss current management and key updates emphasizing the importance of confirming castrate status and proper staging > bit.ly/3WJyokZ

Unveiling the treatment landscape for #mCRPC in #NorthAmerica! What's the current state of #ProstateCancer care? Read this insightful review by Rashid K. Sayyid University of Toronto & Zach Klaassen Georgia Cancer Center on UroToday > bit.ly/3ueVTIa

Evaluating a sequential screening approach for #ProstateCancer using PSA, kallikrein panel, and MRI in the #ProScreen trial. A #JournalClub discussion with Rashid K. Sayyid University of Toronto and Zach Klaassen Georgia Cancer Center > bit.ly/3W0LbPZ

Identifying individual and community-level drivers of disparities in #BladderCancer clinical trials participation. Presentation by Rishi Sekar Michigan Urology. #BCANTT24 written coverage by Rashid K. Sayyid > bit.ly/46FuUVg Bladder Cancer Advocacy Network

Exploring the landscape of #mHSPC treatment in #NorthAmerica. Check out this insightful review on the implementation of treatment strategies and the importance of disease volume and timing of metastasis in guiding optimal therapy > bit.ly/3sBomr7 Zach Klaassen Rashid K. Sayyid

Novel targets and treatment developments in metastatic hormone-sensitive #ProstateCancer. Rashid K. Sayyid University of Toronto and Zach Klaassen Georgia Cancer Center discuss on UroToday > bit.ly/47AvQJR

2024 National Comprehensive Cancer Network (NCCN) Guidelines: Simplifying the management of very low-risk #ProstateCancer. Rashid K. Sayyid & Zach Klaassen join to discuss these updated guidelines on UroToday > bit.ly/3LMhMUG

🌟 Exciting developments in #ProstateCancer treatment! Innovative therapies show promising results in improving OS and QoL for patients. Emerging agents and novel combinations are paving the way for better-targeted treatments > bit.ly/3MnBfLR Zach Klaassen Rashid K. Sayyid

#WatchNow Rashid K. Sayyid & Zach Klaassen discuss the PI-CAI Challenge, showing #AI outperforms radiologists in detecting clinically significant #PCa using MRI. AI found more cancers and fewer false positives, highlighting the potential of this supportive tool > bit.ly/4cCLeaQ

In this population-based cohort study of 5-alpha-reductase-inhibitors (5-ARIs) use prior to prostate cancer (PCa) diagnosis, pre-diagnostic 5-ARI use was not associated with PCa-specific or all-cause mortality. ja.ma/4e0dOUB @Rhamiltonurol Julian Chavarriaga

#WatchNow neil fleshner and Rashid K. Sayyid discuss the surprising results of the #MAST trial, which found no significant benefits of #metformin in preventing #ProstateCancer progression during #ActiveSurveillance, in this conversation on UroToday > bit.ly/4dOiDjK

Enfortumab vedotin and pembrolizumab in untreated advanced #UrothelialCancer #JournalClub. Rashid K. Sayyid University of Toronto & Zach Klaassen Georgia Cancer Center discuss the trial's potential to revolutionize first-line treatment for metastatic urothelial carcinoma > bit.ly/3wSWPDJ

Coming soon! Sept 13-17th #ESMO24 is right around the corner! If you haven't already, #SignUp for summaries by clinicians delivered straight to your inbox, and #StayTuned for coverage throughout the conference > bit.ly/3Z1hUaZ ESMO - Eur. Oncology Zach Klaassen Rashid K. Sayyid Julian Chavarriaga

National Comprehensive Cancer Network (NCCN) 2024 #ProstateCancer guidelines update: PARP inhibitors in focus. Rashid K. Sayyid and Zach Klaassen discuss non-hormonal systemic therapy, highlighting significant changes, particularly the emergence of PARP inhibitors like olaparib and rucaparib > bit.ly/3We9KKj

Coming soon! Sept 13-17th #ESMO24 is right around the corner! If you haven't already, #SignUp for summaries by clinicians delivered straight to your inbox, and #StayTuned for coverage throughout the conference > bit.ly/3Z1hUaZ ESMO - Eur. Oncology Zach Klaassen Rashid K. Sayyid Julian Chavarriaga